[Breaking] Hanmi Science Surges 12.50% in After-Hours Trading on Expectations for Obesity Drug 'Efpelduenatide'...
Hanmi Science recorded a double-digit gain in after-hours trading (post-market trading) on the 7th. In post-market trading that day, the stock price rose 12.50% to 64,800 won, showing strength. Behind this surge lies expectations for the Hanmi Group's obesity treatment business. With Wegovy and Mou
![[Breaking] Hanmi Science Surges 12.50% in After-Hours Trading on Expectations for Obesity Drug 'Efpelduenatide'...](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F08%2F602537%2F93bbefb8f7fe9c3f%2Foriginal.webp&w=1920&q=75)
Hanmi Science recorded a double-digit gain in after-hours trading (post-market trading) on the 7th. In post-market trading that day, the stock price rose 12.50% to 64,800 won, showing strength.
Behind this surge lies expectations for the Hanmi Group's obesity treatment business. With Wegovy and Mounjaro already on the market, whether a domestically developed new drug can enter the obesity treatment market has emerged as a key business focal point for the Hanmi Group.
■ Commercialization of Efpelduenatide Underway... Domestic Product Approval Application Completed
Hanmi Pharmaceutical, the core business subsidiary of Hanmi Science, has been pursuing the commercialization of 'Efpelduenatide,' a GLP-1-based obesity drug it developed in-house. Hanmi Pharmaceutical completed the domestic product approval application for Efpelduenatide in December last year, and in June this year, ahead of its launch in the second half, it introduced its production facilities and commercialization preparations.
The commercialization of Efpelduenatide is a pillar of Hanmi Group's growth strategy in the field of obesity and metabolic diseases. Hanmi Pharmaceutical is also conducting a domestic Phase 3 clinical trial to expand the indication beyond obesity treatment to Type 2 diabetes treatment.
■ Expectations vs. Performance... Approval, Launch, and Prescription Expansion Challenges Remain
However, for expectations regarding new drug development and commercialization to translate into actual revenue and profit, the drug must go through processes such as approval, launch, and prescription expansion. It is difficult to determine the scale of future earnings improvement or stock price trends based solely on the after-hours surge.
As Hanmi Science rose sharply in post-market trading, attention is focused on the concrete progress of the obesity drug business and the stock's movement in the next regular session.
[※ This article is for informational purposes only and does not recommend buying or selling any specific stock. After-hours prices may vary depending on the time of compilation and trading criteria, and whether expectations related to the new drug translate into actual business performance must be confirmed through subsequent disclosures and official announcements. Investment decisions and responsibilities lie with the investor, and AI assistance was used in writing this article.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] U.S. October CPI Rises 0.4% Month-on-Month, Core CPI 0.3% — Markets Watch Fed's Rate Path](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F07%2F589065%2F626fecf2eac1716d%2Fvariants%2Fhero.webp&w=1920&q=75)
![[Seohak!Star] IonQ Named a Quantum Computing Market Leader by Gartner](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F07%2F588503%2F14b3af78be3af851%2Fvariants%2Fhero.webp&w=1920&q=75)
![[Seohak!Star] IonQ Partners with Carahsoft... Full-Scale Entry into U.S. Federal Government Quantum Technology Supply Chain](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F07%2F593384%2Ff0171ed8678444fd%2Fvariants%2Fhero.webp&w=1920&q=75)
